Genome sequencing of human in vitro fertilisation embryos for pathogenic variation screening

Nicholas M. Murphy1,2,3,4*, Tanya S. Samarasekera2, Lisa Macaskill2, Jayne Mullen2 & Luk J. F. Rombauts2,5,6,7

Whole-genome sequencing of preimplantation human embryos to detect and screen for genetic diseases is a technically challenging extension to preconception screening. Combining preconception genetic screening with preimplantation testing of human embryos facilitates the detection of de novo mutations and self-validates transmitted variant detection in both the reproductive couple and the embryo’s samples. Here we describe a trio testing workflow that involves whole-genome sequencing of amplified DNA from biopsied embryo trophectoderm cells and genomic DNA from both parents. Variant prediction software and annotation databases were used to assess variants of unknown significance and previously not described de novo variants in five single-gene preimplantation genetic testing couples and eleven of their embryos. Pathogenic variation, tandem repeat, copy number and structural variations were examined against variant calls for compound heterozygosity and predicted disease status was ascertained. Multiple trio testing showed complete concordance with known variants ascertained by single-nucleotide polymorphism array and uncovered de novo and transmitted pathogenic variants. This pilot study describes a method of whole-genome sequencing and analysis for embryo selection in high-risk couples to prevent early life fatal genetic conditions that adversely affect the quality of life of the individual and families.

Whole-genome sequencing in the IVF clinic. For over two decades, preimplantation genetic testing (PGT) has been available for couples who are aware they carry a genetic condition or have had a child affected by a genetic disease. In vitro fertilisation (IVF) used in conjunction with monogenic PGT is available for couples to prevent transmission of known hereditary monogenic disorders. PGT for aneuploidy screens embryos for large segmental or whole-chromosome copy number changes and is commonly used for older women (>35 years) who have a history of infertility, miscarriages or chromosomally abnormal conceptions1–3. The most recent developments in clinical PGT are low-coverage next-generation sequencing and Karyomapping, which uses a highly polymorphic single-nucleotide polymorphism (SNP) microarray to identify disease-causing haplotypes. Next-generation sequencing PGT for aneuploidy (typically <0.1× depth) is useful for high-throughput screening at a reasonable cost for detecting chromosomal aneuploidies, structural variations and large copy-number variations (CNVs)4–6. In addition to pedigree analysis for monogenic disorders, Karyomapping has been reported to identify partial chromosomal aneuploidies as small as 1.8 Mb7.

For couples seeking to ascertain their risk of having an affected child, around 6,000 diseases exist that may be genetically screened for8. A mutation or disease-causing variant in one or both copies of approximately 5,000 human genes can cause a syndromic disease or phenotype9–14. Between 0.5–5% of infants are born with a genetic condition or disorder15,16. The preconception genetic screening panels that are available to determine a couple’s carrier status for disease-causing genetic variants are limited to a subset of high-risk genes17. Currently, preconception screening and PGT are performed as separate unlinked tests17. An estimated 74 de novo SNP mutations are introduced at embryogenesis, which, when expressed dominantly or as a compound heterozygote, result in severe pathogenic phenotypes18–20.

1Genetic Technologies Ltd., Victoria, Australia. 2Monash IVF, Clayton, Victoria, Australia. 3GenEmbryomics Pty. Ltd., Victoria, Australia. 4Drug Delivery Disposition and Dynamics, Faculty of Pharmacy and Pharmaceutical Sciences, Parkville, Melbourne, Victoria, Australia. 5Centre for Reproductive Health, Hudson Institute of Medical Research, Clayton, Victoria, Australia. 6Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia. 7Monash Women’s & Newborn Program, Monash Health, Victoria, Australia. *email: Nicholas.murphy@monash.edu
With the declining cost and increased availability of whole-genome sequencing, we sought to explore the design of combined preconception screening and embryo PGT using whole-genome sequencing to detect disease-causing genetic variants in couples and their embryos in accordance with recommended practice guidelines. We investigated whether whole-genome sequencing of IVF-conceived embryos could screen for hereditary syndromic genetic diseases in addition to identifying the more technically challenging syndromes resulting from de novo mutations. To date, whole-genome sequencing has been used in a limited number of assisted reproduction cases, principally due to the high cost of high-throughput sequencing. We hypothesised that whole-genome sequencing of preimplantation embryos combined with sequencing genomic DNA from both parents could address the limitations associated with current PGT techniques. The aim was to use whole-genome sequencing analysis to screen embryos for pathogenic variants that would result in severe childhood-onset diseases.

For this pilot study, we sequenced the genomes of five IVF couples and 11 of their IVF embryos that had previously undergone clinical PGT for familial diseases with Karyomapping. The whole-genome amplified trophectoderm cell biopsy samples and genomic DNA of the parents’ samples were used as template DNA for library generation for whole-genome sequencing. Each embryo’s resolved genome sequence was triangulated using multiple trio testing of their parents’ sequences for confirmation of variant status and vice versa. To detect clinically actionable pathogenic variations, multiple trio testing of the parental and the embryo genomes was performed. This was followed by variant annotation using databases to grade variant pathogenicity and the use of pathogenicity prediction algorithms for inherited and de novo mutations and variants of unknown significance. Detecting disease-causing pathogenic variants necessitated the use of inheritance-mode filtering to exclude false positives caused by sequencing artefacts. For each of the major modes of inheritance, curatable variant filter and classification sets were generated to detect known ClinVar archive pathogenic variants. Variants of unknown significance were classified using a range of pathogenicity prediction algorithms and functional annotation databases. The threshold for classifying candidate pathogenic variants was based on pathogenic and likely pathogenic ClinVar categories. For differentiating between type I and type II error calls for de novo mutations, we used the variant allele frequency (VAF) and quality by depth (QD) metric to filter false-positive pathogenic variants in combination. The purpose of this was to detect inherited pathogenic and unacceptably high-risk de novo variations that would be clinically actionable and to guide personalised diagnosis and treatment. Our study to design and test a framework to determine clinically actionable pathogenic variants is, to our understanding, the first of its kind.

**Methods**

**Study participants.** Couples who had PGT for single gene disorders provided written informed consent to having whole-genome sequencing on themselves and their biopsied embryos included in the study. Each participant was given the option to have the results of their genomic DNA and their biopsied embryo samples reported or withheld. All participating couples consented to whole-genome sequencing and elected to receive results for themselves and their tested PGT embryos. The study and protocol were approved by the Monash Health Human Research Ethics Committee (Ref: HREC/17/MonH/286) and all experiments were performed in accordance with protocol guidelines and regulations.

**Library preparation and sequencing.** Genomic DNA from five couples who had been used as reference templates for PGT using Karyomapping were selected for whole-genome sequencing. The DNA had been extracted from whole blood using a ReliaPrep™ Blood genomic DNA Miniprep System (Promega, USA). For the isolation of embryonic DNA, intracytoplasmic sperm injection method created embryos belonging to the five PGT couples underwent trophectoderm biopsy, using laser or mechanical techniques, on day five or six of culture to remove 4–10 trophectoderm cells. Biopsied cells were washed three times in a solution of 1× phosphate-buffered buffer (Cell Signalling Technologies, USA) and 1× polyvinylpyrrolidone (Cook Medical, Australia) followed by whole-genome amplification by multi-displacement amplification with SureMDA system (Illumina, USA) as per manufacturer’s instructions. Samples for whole-genome sequencing were selected based on Karyomapping quality control metrics, which indicated a SNP call-rate on the HumanCytoSNP-12 BeadArray of >96% and allele dropout and miscall rates of <1%. A 1 ug sample of parental genomic DNA and embryo whole-genome amplification products were sent to BGI Genomics (Tai Po, Hong Kong) for sequencing with the BGI-SEQ500. Briefly, the DNA samples were fragmented to approximately 350 bp with a E220 Covaris (Covaris Inc., USA) followed by end-repair, adaptor ligation and amplification by ligase-mediated polymerase chain reaction, single strand separation and cyclisation. DNA nanoballs were produced with rolling-circle amplification, placed in patterned nanoarrays which are 100 bp paired-end reads on a BGI-SEQ500.

**Read processing.** Standard raw read processing through to variant call format was performed in accordance with Genome Analysis Toolkit best practices by the BGI Genomics Online portal pipeline. Raw reads were mapped to the human reference genome (GRCh37/IG19) with Burrows-Wheeler Aligner. polymerase chain reaction duplicates were removed using Picard tools, local realignment was undertaken with Genome Analysis Toolkit and variants were called with HaplotypCaller using the variant quality score recalibration method.

**SNP and indel analysis.** Analysis was guided by the Standards and Guidelines from the American College of Medical Genetics for interpretation of sequence variants. Clinically actionable variants were defined as those that could be justified in requesting for screening by an accredited medical ethics committee. Each parental and embryo binary alignment map (BAM) and raw variant call format files were imported into VarSeq (GoldenHelix, USA). Variant filtering workflows were arranged for the inheritance modes of dominant heterozygous, recessive homozygous, compound heterozygous, X-linked, de novo and a low-specificity
high-sensitivity failsafe filter with a low depth threshold (read depth >1) and was missing the genotype quality filter (Supplementary Table 3). The failsafe filter therefore having intentionally high number of false positives for manual curation (Fig. 1). For variants of unknown significance or conflicting variants, a stringent pathogenicity functional prediction filter was set using the following prediction algorithms: SIFT, Polyphen2 HVAR, MutationTaster2, MutationAssessor, FATHMM and FATHMM MKL43–47. If more than one of the algorithms predicted a variant as damaging, the variant was retained. Variants were then filtered by MPC scores >2 and a final Phred-scaled CADD score of >35 concluded the mutation prediction filter set48,49. Short tandem repeats

Figure 1. Filter sets for pathogenic variant detection from the classifications of variants: (A) variants classified as ‘likely pathogenic’ or ‘pathogenic’, (B) unclassified variants with a potentially feasibly damaging likelihood and (C) copy number variant calling pipelines.
were calculated with ExpansionHunter version 2.5.5 using the default 17 tandem repeat loci to determine short tandem repeat numbers on embryos and parents\(^\text{25}\). Calculation was performed at BGI Genomics for the following loci provided by ExpansionHunter version 2.5.5: cbl proto-oncogene (CBL), atrophin 1 (ATN1), ataxin 2 (ATXN2), ataxin 3 (ATXN3), junctophilin 3 (JPH3), calcium channel, voltage-dependent, P/Q type, alpha 1A subunit (CACNA1A), dystrophia myotonica-protein kinase (DMPK), cystatin B (CSTB), ataxin 10 (ATXN10), ataxin 7 (ATXN7), huntingtin (HTT), protein phosphatase 2, regulatory subunit B beta (PPP2R2B), ataxin 10 (ATXN1), chromosome 9 open reading frame 72 (C9ORF72), frataxin (FXN), androgen receptor (AR) and fragile X mental retardation 1 (FMR1) on all embryo and parental samples.

**Copy number and structural variation.** CNVs were called using CNVnator (v.0.2.7)\(^\text{51}\) and structural variations with Breakdancer\(^\text{26}\) and CREST\(^\text{53}\). A secondary, overlapping CNV discovery analysis was performed by binning into 10 kb windows, filtering by calling loss of heterozygosity (LoH) in more than 95% of variants in flagged regions\(^\text{54,55}\) and annotating using ClinGen Gene Dosage Sensitivity (27-09-2017 release). Structural variations were called and included in the analysis using Breakdancer\(^\text{22}\). CNVnator and Breakdancer calls were imported into Varseq and then compared with the inherited CNVs from each parent and categorised as having dosage pathogenicity for either haploinsufficiency or triplosensitivity. LoH regions (>100 and 95% of variants) were trio-called compared with the parental LoH regions. Filtering was applied for the haploinsufficiency and triplosensitivity categories of 'sufficient evidence for dosage pathogenicity' or 'gene associated with autosomal recessive phenotype' and called for pathogenicity using the target copy number state for proband per sample. This was performed by applying a ratio of >2.0 with a Z-score of >0 for duplications and <0.5 with a Z-score of <0, a mean targeted depth >5 and a lack of quality control flags (high control variation, low control depth, low Z-score or within regional interquartile range) for detecting true positive CNVs. CNVs with recessive inheritance were cross-checked against the autosomal recessive SNP and indel variants.

### Results

**PGT variant validation.** Sequencing depth was comparable between the amplified trophectoderm-biopsy DNA from embryos and the parents' from genomic DNA (mean depth of 48.2× versus 46.1×). Embryo reads were equivalent to the couple's genomic DNA samples for raw and clean reads, bases aligned and transitions to transversion ratios of 2.071 and 2.081 (Supplementary Table 1 and Fig. 1a). Genome coverage for embryos and couples was comparable at sequencing depths of 4× and 10×. However at 20×, genome coverage was relatively decreased for biopsied embryos at 87.5% compared with 96.4% from genomic DNA (Supplementary Figs. 1b, 4a,b). Therefore, with the exception of the failsafe filter, variant filter sets each had the depth threshold at >10× coverage.

Assembly and mapping for the SNP and indel calls were highly concordant between embryos and couples (Supplementary Fig. 1c–f), except for novel SNPs, which averaged 85,527 (standard deviation [SD] 29,576.6) variants in embryos and 21,663 (SD 1102.4) variants for couples. This was reflected in the high number of LoH (Supplementary Fig. 1c–f), except for novel SNPs, which averaged 85,527 (standard deviation [SD] 29,576.6) variants in embryos and couples. With the exception of the failsafe filter, variant filter sets each had the depth threshold at >10× sequencing depths of 4×.

**De novo mutations.** As expected for the couple's male and female partners genomic DNA samples, non-homozygote VAFs showed a normal distribution, with the average centred at 0.5 (indicating 50% of reads per base, Supplementary Fig. 2b). The embryos homozygote VAF distribution ranged from 0.08 to 0.34 with an average peak at 0.26 and maximum at 0.12 (Supplementary Fig. 2a). This low embryo VAF is believed to represent the absence of any low allele frequency CNVs. The embryos heterozygote VAF distribution ranged from 0.08 to 0.34 with an average peak at 0.26 and maximum at 0.12 (Supplementary Fig. 2b). The embryos heterozygote VAF distribution ranged from 0.08 to 0.34 with an average peak at 0.26 and maximum at 0.12 (Supplementary Fig. 2a). This low embryo VAF is believed to represent the absence of any low allele frequency CNVs. The embryos heterozygote VAF distribution ranged from 0.08 to 0.34 with an average peak at 0.26 and maximum at 0.12 (Supplementary Fig. 2a).

### Variant trio-calling.

Three of the five couples had undergone PGT for autosomal dominant conditions, one for an autosomal recessive condition and one for an X-linked condition (Table 1). To confirm the embryo PGT results, in three of the five couples at least one euploid embryo was available (i.e. affected, carrier or unaffected). To determine the concordance between the whole-genome sequencing results to the HumanCytoSNP-12 BeadArray platform used for the couples clinical Karyomapping cycles, assessment of heterozygote calls (~75,000 variants) indicated >99.0% concordance with whole genome sequencing calls. Comparing the results of the pathogenic variants previously diagnosed during monogenic PGT cycles using Karyomapping to those obtained through whole-genome sequencing indicated complete concordance for both couples and embryos (Table 1). One embryo's PGT variant had a substantially lower than expected VAF (0.143; 3/21 reads) but as this was a transmitable variant for it was called by the filter pipeline.

**Pathogenic and predicted pathogenic variant detection in embryos.** For the recessive filter there was an average of 0.82 transmitted pathogenic variants found in dbSNP per embryo (build 151, ranging between 1 and 2 stars for ClinVar review status, 0 stars representing no assertion criteria or minimal evidence, up to 4 stars
for clinical practice guideline). This is compared to an average of 1.27 non-inherited variants per embryo that were predicted pathogenic (Fig. 2, excluding variants for which the couples had originally sought PGT). In one of the couples, both were heterozygote carriers of the CTRF ΔF508 mutation and resulted in a heterozygote in at least one embryo.

For the dominant filters, 1.27 pathogenic variants per embryo were in dbSNP, compared to a mean of 0.45 non-dbSNP predicted pathogenic variants. To detect transmitted pathogenic or predicted pathogenic variants occurring in regions of allele dropout and/or low-coverage in the amplified embryo DNA compared to parental sequences that used genomic DNA, LoH was used (>0.5, indicating the high likelihood of false-positive calls. Addition of the QD minimum threshold to the unclassified filters for QD values of the couples, both were heterozygote carriers of the epidermolytic hyperkeratosis Autosomal Dominant 1 x affected SNP. In embryo samples, most of the loci tested provided at least one concordant call in terms of transmission exactness. At three loci, both alleles were discordant: FMR1, ATXN1 and ATXN3.

**Tandem repeat disease loci analysis.** For the 17 loci that Expansion Hunter assessed the tandem repeat number at known disease-causing loci, no parental samples indicated pathogenic repeat numbers. In embryo samples, most of the loci tested provided at least one concordant call in terms of transmission exactness. At three loci, both alleles were discordant: FMR1, ATXN1 and ATXN3.

**Copy-number and structural variations.** CNVs were assessed by direct transmission and binning reads in 10 kb windows and comparing against inheritance and ClinGen dosage sensitivity scores for pathogenicity. CNVs calls were higher in the embryos compared to parental samples, except for inter-chromosomal structural variations and structural deletions, suggesting a high false-positive rate (Supplementary Fig. 1 and Supplementary Table 1). As anticipated from the Karyomapping results, no pathogenic CNVs were detected (Fig. 3). There was a mean of 2.0 deleterious autosomal recessive structural variations for both couples and embryos compared with a mean of 5.21 and 8.05 structural variations for couples and embryos, respectively, for which triplosensitivity was contributing as autosomal recessive.

**Discussion**
The purpose of this study was to develop a method of whole-genome sequencing analysis that could be used to screen human embryos for pathogenic variants. To achieve this, we firstly used parental genome sequences to identify the transmitted variants. Embryo biopsy samples that had undergone multiple displacement amplification and parental genomic DNA samples obtained from blood were used as templates for generating DNA libraries that were subsequently sequenced. Sequenced genomes of embryos and parents were analysed using variant annotation databases and functional prediction algorithms to detect the transmission or introduction of pathogenic mutations. Parallel filter sets were arranged to filter separately to predict unacceptably high-risk or known pathogenic variations, CNVs or chromosomal scale rearrangements. Multiple trio-testing of each embryo against the couples’ genomes facilitated the detection of transmitted and de novo variants calling as likely pathogenic or pathogenic by disorder or variant categorisation. The complete concordance between variant calls on
the SNP array and whole-genome sequencing results indicated that inherited variants were confidently detected via trio-testing.

De novo variant calling in embryos presented a unique challenge. A custom VAF filter was required to minimise false positives that were likely introduced as a result of multiple displacement amplification from single base substitutions. The VAF soft threshold of <0.35 and quality scores guided the de novo variant calling. This threshold was marginally higher than the reported de novo false-positive threshold of 0.28 to 0.33. We used VAF, base quality metrics and functional interpretation to determine pathogenicity to differentiate between true- and false-positive calls. Strict filtering of de novo mutations and the risk of under-calling was offset by the failsafe filter set, which was intended to perform a low-sensitivity function that would pick-up clinically actionable variants. Individual curation of these candidate variants indicated that these were likely to be false positives based on low VAF. To validate specific de novo variants, performing direct polymerase chain reaction following embryo re-biopsy or from DNA obtained from culture media are feasible options. The known PGT variant occurring at an extraordinarily low VAF (0.143) in one of the embryos exemplifies the necessity to have specific filter sets for each mode of transmission and variant subtype.

To avoid pathogenic variants being transmitted in low or missing coverage regions and being undetected, an untransmitted variant filter manually examined uncalled variants flanking haplotypes to confirm the result at each site. The uniform coverage exhibited by multiple displacement amplification of DNA from the embryos

Figure 2. Bar graphs of the filter system for determining the clinically relevant variants proposed for embryo selection for each mode of inheritance: (A) filter sets for determining clinically relevant variants classified as either likely pathogenic or pathogenic and (B) filter sets for variants not yet classified but potentially damaging or disease causative. Filters in each row are successively added to the total number of variants remaining.
suggests that the likelihood of a pathogenic de novo mutation arising in a region with low coverage is remote. These type 2 errors are further mitigated by the failsafe low-coverage assessment filter, although LoH and VAF filtering can guide manual decision-making. We avoided imputation for regions of LoH to focus on what could be ascertained directly from the data.

For this study we performed pathogenic variant detection of known likely pathogenic and pathogenic variants in accordance with available databases of variants that have high to complete penetrance. Further work is required to stratify the outcomes of compound heterozygotes in which at least one variant is ranked likely pathogenic. Here, we used a non-exhaustive list of essential genes combined with known developmental delay genes. A list of core disease genes for embryo genome screening is necessary to avoid overcalling.

For CNV calls, the recommended 10 kb size for the bins represents the lower limit for the annotation software, which coincides with the upper limit for variant call format file indels. For variations exceeding 10 kb, variant calls were inconsistent between the couples and the embryos, and a read-binning approach was required to confidently call CNV and structural variations. CNV detection via analysis of 10 kb bins overcomes the issue of high false-positive CNV calls, as evidenced by the concordance between partner and embryo genomes. The effective 10 kb upper size limit of indels is conveniently bridged by performing binned CNV analysis in 10 kb blocks. This addressed the issue of the limitations of multiple displacement amplification, enabling comprehensive compound CNV detection of inherited variants and de novo mutations. Short tandem repeat loci yielded inconsistent results for parental and embryo genomes, an observation not pursued further. Clinically, it would be beneficial to use preconception short tandem repeat assessment of premutations at loci responsible for short tandem repeat disorders.

There are limitations to this pilot study and areas where further work is required. Pathogenic de novo mutations occurring in a region of no or low coverage will be a challenging limitation to overcome. Further work is required to determine the likelihood of one of these highly improbable scenarios occurring. A second limitation is the threshold of VAF, which obfuscates de novo mutation calling. The need to determine the validity of de novo mutation calls meant filtering out variants which were likely polymerase base incorporation errors of the MDA, allele dropout or mis-aligned reads, generating false-positive variants. The advantages to embryo development and implantation rates conferred by the technique of trophectoderm biopsy of 4–8 cells serves as an additional benefit by maximising embryo genome sequencing coverage. Although the VAF suggested that the type of mutation varies in mean VAF, this was not explored in the present study. Minimising amplification and sequencing artefacts through allelic ratio and haplotype scoring effectively minimises the number of candidate de novo mutations to a number that can be, if necessary, curated. An ethnicity-specific penetrance magnitude metric to guide the level of pathogenicity would be highly relevant for IVF-based screening.

Controversy regarding whole-genome sequencing in IVF is reflected in contemporary questions of the utility of transferring chromosomally mosaic embryos in PGT aneuploidy screening. We provide compelling evidence in favour of using whole-genome sequencing for screening embryos for pathogenic, severe disease-causing and
unacceptably high-risk de novo mutations. Offering clinical genome screening of embryos in the IVF clinic, either as a standalone test or after low-coverage PGT, is based on evidence that the major classes of pathogenic variation can be reliably detected. In addition to comprehensive genomic screening, several embryo development-related aneuploidies, that cannot currently be screened for via next-generation sequencing based PGT (i.e. 69,XXX and low-level mosaicism), can be directly observed and screened via this protocol because of its unlimited resolution of structural variation. Although low-coverage PGT for aneuploidy is effective for detecting large (>10 Mbp) chromosomal aneuploidies, 1–2% of conceptions carry a de novo CNV or structural aneuploidy of >100 kb, a significant gap in the detection threshold.

The concept of applying whole-genome sequencing for PGT is contentious, the main concern being the sensitivity and specificity of a testing system and the ethical questions that arise. The ongoing emotional and psychological burden born by the parents and the monetary cost of support from a healthcare system for caring for a couple's subfertility can be diagnosed and factored into the initial screening to produce a viable pregnancy. Additionally, pharmacogenetics guided stimulation regimens for oocyte retrieval and personalised embryo culture media based on metabolic pathway analysis could be ascertained.

The method we propose for screening embryos for pathogenic content has provided evidence of the feasibility of whole-genome sequencing to screen biopsied IVF embryos for severe disease-causing pathogenic variants. By including de novo mutations and premutation short tandem repeat disorders in preconception testing, the risk of childhood disease with known genetic aetiologies can be significantly reduced, should any couple choose to. The discovery of the CFTR ΔF508 mutation in one of the couples having PGT for an alternative mutation exemplifies the justification, relevance and utility of this study.

This study is the first to demonstrate the validity of using whole-genome sequencing in the IVF clinic. Further research is required for stratifying variant penetrance across ethnicities and expanding the variant data to include variants of unknown significance and idiopathic disorders with polygenic risk is warranted.

Received: 26 February 2019; Accepted: 13 February 2020;
Published online: 02 March 2020

References

1. Sullivan-Pyke, C. & Dokras, A. Preimplantation Genetic Screening and Preimplantation Genetic Diagnosis. Obstetrics and Gynecology Clinics of North America 45, 113–125, https://doi.org/10.1016/j.gocg.2017.10.009 (2018).
2. Chen, H.-F. et al. Preimplantation genetic diagnosis and screening: Current status and future challenges. Journal of the Formosan Medical Association 117, 94–100, https://doi.org/10.1016/j.jfma.2017.09.006 (2018).
3. Munné, S. Status of preimplantation genetic testing and embryo selection. Reproductive BioMedicine Online 37, 393–396, https://doi.org/10.1016/j.rbmo.2018.08.001 (2018).
4. Wells, D. et al. Clinical utilisation of a rapid low-pass whole genome sequencing technique for the diagnosis of aneuploidy in human embryos prior to implantation. Journal of Medical Genetics 51, 553 (2014).
5. Van der Aa, N., Esteki, M. Z., Vermeesch, J. R. & Voet, T. Preimplantation genetic diagnosis guided by single-cell genomics. Genome Medicine 5, 71–71, https://doi.org/10.1186/1755-8756-5-71 (2013).
6. Handsyde, A. H. et al. Karyomapping: a universal method for genome wide analysis of genetic disease based on mapping crossovers between parental haplotypes. Journal of Medical Genetics 47, 651–658 (2010).
7. Harper, J. C. et al. Recent developments in genetics and medically assisted reproduction: from research to clinical applications. European Journal of Human Genetics: EJHG 26, 12–33, https://doi.org/10.1038/s41431-017-0016-x (2018).
8. Online Mendelian Inheritance in Man, O. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD). (2000).
9. Landrum, M. J. et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res. 44, https://doi.org/10.1093/nar/gkv1222 (2016).
10. Sherry, S. T. et al. dbSNP: the NCBI database of genetic variation. Nucleic Acids Research 29, 308–311 (2001).
11. UniProt: the universal protein knowledgebase. Nucleic Acids Research 45, D158–D169, https://doi.org/10.1093/nar/gkw1099 (2017).
12. Amberger, J. S., Bocchini, C. A., Schiedt, F. S. & Hamosh, A. OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders. Nucleic Acids Research 43, D789–D798, https://doi.org/10.1093/nar/gku205 (2015).
13. Stenson, P. D. et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Human Genetics 136, 665–677, https://doi.org/10.1007/s00439-017-1779-6 (2017).
14. Rappaport, N. et al. In Current Protocols in Bioinformatics (John Wiley & Sons, Inc. 2002).
15. Verma, I. C. & Puri, R. D. Global burden of genetic disease and the role of genetic screening. Seminars in Fetal and Neonatal Medicine 20, 354–363, https://doi.org/10.1016/j.siny.2015.07.002 (2015).
16. Jackson, M., Marks, L., May, G. H. W. & Wilson, J. B. The genetic basis of disease. Essays in biochemistry 62, 643–723, https://doi.org/10.1042/EBC20170053 (2018).
17. Halam, L. M. et al. Preimplantation genetic diagnosis versus prenatal diagnosis—decision-making among pregnant FMR1 premutation carriers. Journal of Assisted Reproduction and Genetics 35, 2071–2075, https://doi.org/10.1007/s10815-018-1293-3 (2018).
18. Acuna-Hidalgo, R. et al. Post-zygotic Point Mutations Are an Underrecognized Source of De Novo Genomic Variation. The American Journal of Human Genetics 97, 67–74, https://doi.org/10.1016/j.ajhg.2015.05.008 (2015).
19. Kondrashov, A. S. Direct estimates of human per nucleotide mutation rates at 20 loci causing mendelian diseases. Human Mutation 31, 12–27, https://doi.org/10.1002/humu.10147 (2003).
20. Acuna-Hidalgo, R., Veltman, J. A. & Hoischen, A. New insights into the generation and role of de novo mutations in health and disease. Genome Biology 17, 241, https://doi.org/10.1186/s13059-016-1110-1 (2016).
21. Kumar, A. et al. Whole genome prediction for preimplantation genetic diagnosis. Genome Medicine 7, 35, https://doi.org/10.1186/s13073-015-0160-4 (2015).
22. Peters, B. A. et al. Detection and phasing of single base de novo mutations in biopsies from human in vitro fertilized embryos by advanced whole-genome sequencing. Genome Research 26, 426–434, https://doi.org/10.1101/gr.181255.114 (2015).
23. Dequeker, E. et al. Best practice guidelines for molecular genetic diagnosis of cystic fibrosis and CFTR-related disorders – updated European recommendations. European Journal of Human Genetics: EJHG 17, 51–65, https://doi.org/10.1038/ejhg.2008.136 (2009).
24. Burke, W., Tarini, B., Press, N. A. & Evans, J. P. Genetic screening. *Epidemiologic Reviews* **33**, 148–164, https://doi.org/10.1093/epirev/mxr008 (2011).

25. Natesan, S. A. *et al.* Genome-wide karyomapping accurately identifies the inheritance of single-gene defects in human preimplantation embryos in vitro. *Genetics in Medicine* **16**, 838–845, https://doi.org/10.1038/gim.2014.45 (2014).

26. Natarajan, P. *et al.* Aggregate penetrance of genomic variants for actionable disorders in European and African Americans. *Science Translational Medicine* **8**, 364ra151–364ra151, https://doi.org/10.1126/scitranslmed.aag2367 (2016).

27. Landrum, M. J. *et al.* ClinVar: public archive of relationships among sequence variation and human phenotype. *Nucleic acids research* **42**, D980–D985, https://doi.org/10.1093/nrg/dkt113 (2014).

28. Yan, Y. *et al.* Association of Follicle-Stimulating Hormone Receptor Polymorphisms with Ovarian Response in Chinese Women: A Prospective Clinical Study. *PLoS One* **8**, e78138, https://doi.org/10.1371/journal.pone.0078138 (2013).

29. Wosnitzer, M. S. Genetic evaluation of male infertility. *Translational Andrology and Urology* **3**, 17–26, https://doi.org/10.3978/j.issn.2223-6833.2014.02.04 (2014).

30. Patch, A. -M. *et al.* Germline and somatic variant identification using BGISEQ-500 and HiSeq X Ten whole genome sequencing. *PLoS One* **13**, e0190264, https://doi.org/10.1371/journal.pone.0190264 (2018).

31. Van der Auwera, G. A. *et al.* From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. *Current protocols in bioinformatics/Editorial Board, Andreas D. Baxevanis *et al.*, [et al.] **11**, 11.10.11–11.10.33, https://doi.org/10.1002/0471250953.bi111043 (2013).

32. Van der Auwera, G. A. *et al.* From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline. *Current Protocols in Bioinformatics* **43**, 11.10.11–11.10.33, https://doi.org/10.1002/0471250953.bi111043 (2013).

33. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. *Bioinformatics* **26**, 589–595, https://doi.org/10.1093/bioinformatics/btp698 (2010).

34. Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows–Wheeler transform. *Bioinformatics* **26**, 589–595, https://doi.org/10.1093/bioinformatics/btp698 (2010).

35. Picard Tools. http://broadinstitute.github.io/picard

36. DePristo, M. A. *et al.* A framework for variation discovery and genotyping using next-generation DNA sequencing data. *Nature Genetics* **43**, 491–498, https://doi.org/10.1038/ng.666 (2011).

37. McKenna, A. *et al.* The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Research* **20**, https://doi.org/10.1101/gr.107524.110 (2010).

38. Rehm, H. L. *et al.* ACMG clinical laboratory standards for next-generation sequencing. *Genetics in Medicine: Official Journal of the American College of Medical Genetics* **15**, 733–747, https://doi.org/10.1038/gim.2013.92 (2013).

39. Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and the Association for Molecular Pathology. *Genet. Med.* **17**, https://doi.org/10.1038/gim.2015.30 (2015).

40. McDonnell, E., Strasser, K. & Tsang, A. *In Fungal Genomics: Methods and Protocols* (eds Ronald P. de Vries, Adrian Tsang, & Igor V. Grigoriev) 185–208 (Springer New York, 2018).

41. Alankarage, D. *et al.* Identification of clinically actionable variants from genome sequencing of families with congenital heart disease. *Genetics in Medicine* **21**, 1111–1120, https://doi.org/10.1038/gim.2018.1436 (2019).

42. Carter, T. C. & He, M. M. Challenges of Identifying Clinically Actionable Genetic Variants for Precision Medicine. *Journal of Healthcare Engineering* **2016**, 3617572, https://doi.org/10.1155/2016/3617572 (2016).

43. Ng, P. C. & Henikoff, S. SIFT: predicting amino acid changes that affect protein function. *Nucleic Acids Research* **31**, 3812–3814 (2003).

44. Adzhubei, I., Jordan, D. M. & Sunyaev, S. R. Predicting Functional Effect of Human Missense Mutations Using PolyPhen-2. *Current Protocols in Human Genetics/Editorial Board, Jonathan L. Haines et al.*, [et al.] **7**, Unit7.20–Unit7.20, https://doi.org/10.1002/0471142905.hbg070576 (2013).

45. Schwarz, J. M., Cooper, D. N., Schuelke, M. & Seelow, D. MutationTaster2: mutation prediction for the deep-sequencing age. *Nature Methods* **11**, 361, https://doi.org/10.1038/nmeth.2890 https://www.nature.com/articles/nmeth.2890 (2014).

46. Reva, B., Antipin, Y. & Sander, C. Predicting the functional impact of protein mutations: application to cancer genomics. *Nucleic Acids Research* **39**, e118–e118, https://doi.org/10.1093/nar/gkr407 (2011).

47. Shihab, H. A. *et al.* Ranking non-synonymous single nucleotide polymorphisms based on disease concepts. *Human Genetics* **8**, 11–11, https://doi.org/10.1186/1479-7364-8-11 (2014).

48. Samocha, K. E. *et al.* Regional missense constraint improves variant deleteriousness prediction. *bioRxiv*, https://doi.org/10.1101/0471142905.hbg070576 (2011).

49. Kircher, M. *et al.* A general framework for estimating the relative pathogenicity of human genetic variants. *Nature Genetics* **46**, 310–315, https://doi.org/10.1038/ng.2892 (2014).

50. Dolzhenko, E. *et al.* Detection of long repeat expansions from PCR-free whole genome sequence data. *Genome Research*, https://doi.org/10.1101/225672.117 (2017).

51. Abybov, A., Urban, A. E., Snyder, M. & Gerstein, M. CNVnator: An approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. *Genome Research* **21**, 974–984, https://doi.org/10.1101/gr.114876.110 (2011).

52. Fan, X., Abbott, T. E., Larson, D. & Chen, K. BreakDancer – Identification of Genomic Structural Variation from Paired-End Read Mapping. *Current Protocols in Bioinformatics/Editorial Board, Andreas D. Baxevanis *et al.*, [et al.] **11**, 10.1002/0471250953.bi111043 (2013).

53. Yang, L. *et al.* Presence of embryonic DNA in culture medium. *Oncotarget* **8**, 67805–67809, https://doi.org/10.18632/oncotarget.18852 (2017).

54. Matthis, G. *et al.* Guidelines for diagnostic next-generation sequencing. *European Journal Of Human Genetics* **24**, 2, https://doi.org/10.1038/ejhg.2015.226, https://www.nature.com/articles/ejhg2015226#supplementary-information (2015).

55. Vaz-de-Macedo, C. & Harper, J. A closer look at expanded carrier screening from a PGD perspective. *Human Reproduction* **32**, 2015–2016, https://doi.org/10.1093/humrep/dez227 (2017).

56. Harper, J. C. Preimplantation genetic screening. *Journal of Medical Screening* **25**, 1–5, https://doi.org/10.1177/0969141317691797 (2018).
61. Winand, R. et al. In vitro screening of embryos by whole-genome sequencing: now, in the future or never? *Human Reproduction* **29**, 842–851, https://doi.org/10.1093/humrep/deu005 (2014).
62. Chrystoja, C. C. & Diamandis, E. P. Whole Genome Sequencing as a Diagnostic Test: Challenges and Opportunities. *Clinical Chemistry* **60**, 724, https://doi.org/10.1373/clinchem.2013.209213 (2014).
63. McCandless, S. E., Brunger, J. W. & Cassidy, S. B. The Burden of Genetic Disease on Inpatient Care in a Children’s Hospital. *American Journal of Human Genetics* **74**, 121–127 (2004).

**Author contributions**

N.M.M. conceived the project, designed and performed experiments, performed bioinformatics, analysed data and wrote the paper; T.S. gave technical and writing support and conceptual advice; L.M. gave technical, conceptual and writing support and performed experiments; J.M. gave writing support and conceptual advice. L.R. gave writing support and conceptual advice.

**Competing interests**

There are competing funding interests from Monash IVF who contributed to a research grant for the research through the Monash Research and Education Fund. The authors were employed at Monash IVF for the main duration of the study. A provisional patent based on the study method protocol has been submitted.

**Additional information**

**Supplementary information** is available for this paper at https://doi.org/10.1038/s41598-020-60704-0.

**Correspondence** and requests for materials should be addressed to N.M.M.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).

**Publisher’s note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/).

© The Author(s) 2020